Telix Pharmaceuticals Limited (TLX.AX)
| Previous close | 19.05 |
| Open | 19.14 |
| Bid | 17.81 x 0 |
| Ask | 17.89 x 0 |
| Day's range | 17.82 - 19.20 |
| 52-week range | 8.20 - 20.76 |
| Volume | |
| Avg. volume | 1,589,687 |
| Market cap | 5.963B |
| Beta (5Y monthly) | 2.40 |
| PE ratio (TTM) | 118.80 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON[1] trial have been published in The Lancet Oncology, reporting that Telix's first-in-class investigational PET[2] agent, TLX250-CDx (Zircaix®[3], 89Zr-girentuximab), is highly accurate in detecting and characterising clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IRMs).
- PR Newswire
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma (GBM), the most common and aggressive form of primary brain cancer.
- PR Newswire
Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2] agent for the characterisation of progressive or recurrent glioma (brain cancer) from treatment related changes in both adult and pediatric patients.
